tmem231 Antibody

What is TMEM231 and why is it important to study?

TMEM231 is a two-pass transmembrane protein that functions as a component of the Meckel syndrome (MKS) complex at the ciliary transition zone. This protein is critical for organizing the MKS complex and controlling ciliary composition. TMEM231 regulates the localization of ciliary membrane proteins by participating in the formation of a diffusion barrier at the transition zone . Studies have shown that mutations in TMEM231 are associated with serious developmental disorders, including orofaciodigital syndrome type 3 (OFD3) and Meckel syndrome (MKS), which are characterized by kidney cysts, polydactyly, and hepatic ductal plate malformations . Understanding TMEM231's structure and function can provide insights into ciliopathy pathogenesis and potential therapeutic approaches.

How does TMEM231 function at the molecular level?

At the molecular level, TMEM231 works in concert with other transition zone proteins to regulate the ciliary membrane protein composition. TMEM231 interacts with multiple components of the MKS complex, including B9d1, Mks1, Tctn1, Tctn2, Tctn3, Cc2d2a (Mks6), and Tmem17 . Particularly important is its interaction with B9d1, as they are essential for each other's localization to the transition zone. TMEM231 and B9d1 together help localize other MKS complex components, including Mks1, to the transition zone . When TMEM231 function is compromised, proteins like Arl13b and Inpp5e fail to properly localize to cilia, resulting in ciliopathy phenotypes . This interdependence highlights TMEM231's role as a crucial organizer of the transition zone architecture.

What are the common epitopes targeted by TMEM231 antibodies?

TMEM231 antibodies are typically designed to recognize specific regions of the protein that are accessible and immunogenic. While the search results don't specify particular epitopes, TMEM231 antibodies would likely target:

• N-terminal or C-terminal domains that extend outside the membrane, as these regions are more accessible and often more immunogenic

• Unique amino acid sequences that distinguish TMEM231 from other transmembrane proteins

• Conserved regions if the antibody needs to detect TMEM231 across multiple species

Researchers should consider the protein's topology when selecting antibodies, as TMEM231 is a two-pass transmembrane protein with both terminal regions and a loop region between the transmembrane domains potentially accessible for antibody binding .

What are the optimal fixation conditions for TMEM231 immunodetection in different cell types?

For optimal immunodetection of TMEM231, researchers should consider:

• Paraformaldehyde (4%) fixation for 10-15 minutes at room temperature typically preserves TMEM231 localization at the transition zone

• Methanol fixation (100%, -20°C for 10 minutes) may be preferable for certain epitopes and when dual labeling with tubulin antibodies

• For ciliated cell types (e.g., IMCD3, RPE1, or MEFs), mild permeabilization with 0.1-0.2% Triton X-100 is recommended to preserve ciliary structures

• Antigen retrieval may be necessary if fixation masks the epitope

The specific conditions should be optimized based on the particular antibody being used and the cell type under investigation. Based on studies with other transition zone proteins, TMEM231 might require special consideration to preserve its localization pattern at the ciliary base .

How can researchers validate TMEM231 antibody specificity for immunofluorescence studies?

To validate TMEM231 antibody specificity, researchers should implement multiple control measures:

• Use TMEM231 knockout cells or tissues as negative controls (the punctate staining at the ciliary base should be absent)

• Perform peptide competition assays, where pre-incubation of the antibody with excess immunizing peptide should abolish specific staining

• Compare staining patterns with multiple antibodies targeting different epitopes of TMEM231

• Verify colocalization with known transition zone markers like B9d1, Mks1, or other MKS complex components

• Use tagged versions of TMEM231 (e.g., LAP-tagged or FLAG-tagged) as positive controls and for comparison with antibody staining patterns

• Confirm that staining is consistent with TMEM231's known localization at the transition zone, which appears as a distinct punctate pattern at the ciliary base

Using TMEM231-null MEFs, as described in the studies where TMEM231 knockout mice were generated, would provide an excellent negative control for antibody specificity testing .

What co-immunoprecipitation protocols are most effective for studying TMEM231 protein interactions?

For studying TMEM231 protein interactions through co-immunoprecipitation, researchers should consider:

• Cell lysis conditions: Use mild detergents (0.5-1% NP-40 or Triton X-100) in buffers containing protease inhibitors to preserve protein-protein interactions

• Pre-clearing: Implement a pre-clearing step with protein A/G beads to reduce non-specific binding

• Antibody selection: Use validated antibodies targeting TMEM231 or epitope tags (FLAG, V5, etc.) if using tagged versions

• Controls: Include IgG controls and, when possible, TMEM231 knockout cells as negative controls

• Washing: Use stringent but not excessive washing to remove non-specific interactions while preserving genuine ones

Based on published research, TMEM231 has been successfully co-immunoprecipitated with other transition zone proteins like B9d1 and Mks1 . For tagged versions, researchers have used FLAG-tagged Tmem231 and V5-tagged B9d1 for co-immunoprecipitation studies, demonstrating that disease-associated TMEM231 mutations may affect protein stability but not necessarily protein-protein interactions .

How can TMEM231 antibodies be used to investigate ciliopathy disease mechanisms?

TMEM231 antibodies serve as valuable tools for investigating ciliopathy disease mechanisms through several approaches:

• Comparative immunostaining of patient-derived cells vs. controls to assess TMEM231 localization and expression

• Analysis of transition zone architecture in cells expressing disease-associated TMEM231 variants

• Examination of ciliary protein composition in disease models using TMEM231 antibodies alongside markers for ciliary membrane proteins (e.g., Arl13b, Inpp5e)

• Screening for transition zone defects in patient samples from ciliopathy cohorts

• Investigating the effects of TMEM231 mutations on downstream signaling pathways (e.g., Hedgehog signaling)

Research has shown that TMEM231 mutations disrupt the localization of proteins including Arl13b and Inpp5e to cilia, resulting in phenotypes characteristic of MKS, such as polydactyly and kidney cysts . By using TMEM231 antibodies alongside other ciliary markers, researchers can assess how disease-associated mutations affect transition zone function and ciliary composition, providing insights into disease pathogenesis .

What are the challenges in detecting TMEM231 protein variants associated with ciliopathies?

Detecting TMEM231 protein variants associated with ciliopathies presents several challenges:

• Expression levels: Disease-associated mutations may affect protein stability and expression levels. For example, studies have shown that mutations p.Asn90Ile and p.Pro125Ala compromise TMEM231 protein levels

• Epitope accessibility: Mutations may alter protein conformation, potentially masking antibody epitopes

• Localization patterns: Disease variants may display altered subcellular localization, requiring careful analysis of multiple cellular compartments

• Specificity: Distinguishing specific variants may require specialized antibodies or complementary techniques

• Sensitivity: Low abundance of mutant proteins may necessitate signal amplification methods

Researchers studying the p.Leu81Phe, p.Pro125Ala, p.Asn90Ile, and p.Ala216Pro TMEM231 variants found that while these mutants retain the ability to interact with B9d1, they show compromised function in localizing Arl13b to cilia and restoring B9d1 localization to the transition zone . These findings demonstrate the need for multiple analytical approaches beyond simple protein detection to fully characterize the functional impact of disease-associated variants.

How does the evolutionary conservation of TMEM231 affect antibody selection for cross-species studies?

The evolutionary conservation of TMEM231 is an important consideration when selecting antibodies for cross-species studies:

• Sequence homology: TMEM231 shows conservation among chordates, with some regions (like Pro125) conserved even in ciliated protists

• Functional domains: The most conserved regions often correspond to functional domains critical for protein-protein interactions or membrane insertion

• Epitope selection: Antibodies targeting highly conserved epitopes are more likely to recognize TMEM231 across species

• Species validation: Researchers should verify antibody reactivity against each target species rather than assuming cross-reactivity

• Ortholog considerations: In C. elegans, the TMEM-231 ortholog has conserved transition zone localization and function, suggesting evolutionary conservation of key domains

For comparative studies between mice, humans, and other model organisms, researchers should select antibodies targeting highly conserved regions of TMEM231. The absence of TMEM231 orthologs in unciliated organisms further supports its conserved role in ciliary biology and suggests that certain epitopes may be unique to ciliated organisms .

How can researchers optimize Western blotting protocols for detecting TMEM231?

For optimal Western blot detection of TMEM231, researchers should consider the following protocol adjustments:

• Sample preparation: Use stringent lysis buffers (containing SDS and reducing agents) to fully solubilize this transmembrane protein

• Gel percentage: Opt for 10-12% polyacrylamide gels to properly resolve TMEM231 (predicted molecular weight ~36 kDa)

• Transfer conditions: Use semi-dry or wet transfer with methanol-containing buffers for efficient transfer of transmembrane proteins

• Blocking: BSA-based blocking solutions may be preferable to milk for phospho-specific antibodies

• Antibody incubation: Extended incubation times (overnight at 4°C) may improve detection of low-abundance TMEM231

• Controls: Include positive controls (overexpressed TMEM231) and negative controls (TMEM231 knockout samples)

• Detection: Use enhanced chemiluminescence or fluorescent secondary antibodies for sensitive detection

Studies have shown that some disease-associated mutations like p.Asn90Ile and p.Pro125Ala can compromise TMEM231 protein levels , so researchers should be aware that protein abundance may vary significantly depending on the experimental context or disease model being studied.

What strategies can improve immunofluorescence detection of TMEM231 at the ciliary transition zone?

To enhance immunofluorescence detection of TMEM231 at the ciliary transition zone, researchers should implement these strategies:

• Ciliation induction: Serum starve cells (24-48 hours) to induce maximum ciliation before fixation

• Fixation optimization: Test both PFA and methanol fixation to determine which best preserves the epitope

• Antigen retrieval: Consider mild antigen retrieval methods if initial staining is weak

• Signal amplification: Use tyramide signal amplification or higher sensitivity detection systems

• Co-staining: Implement dual labeling with axoneme markers (acetylated tubulin) and basal body markers (γ-tubulin) to precisely identify the transition zone

• High-resolution imaging: Use structured illumination microscopy (SIM) or other super-resolution techniques to resolve the transition zone

• Z-stack acquisition: Collect z-stacks to ensure capture of the transition zone plane

TMEM231 localizes to a distinct domain between the basal body and axoneme, appearing as a punctate ring or dot at the ciliary base . Optimizing visualization of this specific localization pattern is crucial for accurately assessing TMEM231 function in experimental studies.

How should researchers quantify changes in TMEM231 localization or expression in comparative studies?

For robust quantification of changes in TMEM231 localization or expression in comparative studies, researchers should:

• Establish consistent imaging parameters: Use identical exposure times, laser power, and detector settings across all samples

• Implement automated analysis: Develop image analysis pipelines that define regions of interest (ROIs) at the transition zone

• Apply appropriate metrics:

  • For localization: Measure fluorescence intensity ratios between transition zone and cytoplasm/background

  • For expression: Quantify integrated density values of TMEM231 signal

• Use internal controls: Normalize TMEM231 signals to stable reference proteins (e.g., γ-tubulin for the basal body)

• Blind analysis: Perform quantification blind to experimental conditions to prevent bias

• Statistical approach: Analyze sufficient numbers of cells (>30 per condition) across multiple independent experiments for statistical robustness

In published studies, researchers have quantified the rescue ability of wild-type versus mutant TMEM231 by measuring the fluorescence intensity of Arl13b at cilia and B9d1 at the transition zone . These quantitative approaches revealed that disease-associated TMEM231 mutations result in significantly reduced function compared to wild-type protein.

How do TMEM231 mutations specifically affect its function in ciliopathy pathogenesis?

TMEM231 mutations affect ciliopathy pathogenesis through several distinct mechanisms:

Interestingly, the severity of clinical presentation does not always correlate with the degree of functional impairment measured in cellular assays. For example, one MKS-associated mutation (p.Asn90Ile) displayed more activity than an OFD3-associated mutation (p.Leu81Phe) in cell-based assays, suggesting that additional factors or genetic modifiers contribute to phenotypic variation .

What are the key differences in TMEM231 pathology between OFD3 and MKS syndromes?

The pathological differences in TMEM231 between OFD3 and MKS syndromes involve several aspects:

• Mutation characteristics: Both syndromes involve hypomorphic TMEM231 mutations, but they affect different aspects of protein function. In OFD3, identified mutations (p.Leu81Phe/p.Pro125Ala) may partially complement each other, suggesting they affect separate functional domains

• Phenotypic severity: MKS represents a more severe ciliopathy phenotype (typically lethal prenatally) compared to OFD3, which presents with "metronome" eye movements, lingual hamartomas, and postaxial polydactyly in addition to cerebellar vermis hypoplasia and moderate intellectual disability

• Renal involvement progression: OFD3 patients studied had normal renal morphology and function at birth but developed end-stage renal failure at 13 and 24 years old, suggesting progressive deterioration rather than developmental malformation

• Genetic burden: The research suggests that MKS samples likely have an increased mutational burden in other ciliary or transition zone genes compared to OFD3-affected individuals, potentially accounting for phenotypic differences

These differences highlight the complex relationship between genotype and phenotype in ciliopathies and underscore the importance of comprehensive genetic analysis alongside functional studies of specific mutations.

What experimental models are most suitable for studying TMEM231 function in ciliopathies?

Several experimental models are particularly valuable for studying TMEM231 function in ciliopathies:

• Mouse models: TMEM231 knockout mice display ciliopathy phenotypes including kidney cysts, polydactyly, and hepatic ductal plate malformations. These models are valuable for studying developmental aspects of ciliopathies

• Mouse embryonic fibroblasts (MEFs): MEFs from TMEM231 knockout mice provide an excellent cellular system for studying transition zone formation, ciliary protein localization, and rescue experiments with wild-type or mutant TMEM231

• C. elegans: The conservation of TMEM-231 function in C. elegans makes this organism valuable for evolutionary studies and high-throughput screening approaches. In worms, TMEM-231 localizes to and controls transition zone formation and function

• Patient-derived cells: Fibroblasts or induced pluripotent stem cells (iPSCs) from OFD3 or MKS patients with TMEM231 mutations offer opportunities to study human-specific aspects of disease pathogenesis

• CRISPR-engineered cell lines: Introducing specific disease-associated TMEM231 mutations into cell lines can help dissect the functional consequences of individual variants

The choice of model system should align with specific research questions. Mouse models are valuable for studying systemic and developmental phenotypes, while cellular models offer advantages for detailed molecular and cell biological investigations of TMEM231 function .

How might TMEM231 antibodies be used to investigate novel ciliary signaling pathways?

TMEM231 antibodies can facilitate investigation of novel ciliary signaling pathways through:

• Proximity labeling approaches: Coupling TMEM231 antibodies with BioID or APEX2 proximity labeling to identify new protein interactions at the transition zone

• Phosphoproteomics: Using TMEM231 antibodies to immunoprecipitate the protein and analyze its phosphorylation state in response to various signaling stimuli

• Super-resolution microscopy: Employing TMEM231 antibodies in multi-color super-resolution imaging to map nanoscale organization of signaling components at the transition zone

• Temporal dynamics: Using TMEM231 antibodies in live-cell imaging approaches to track dynamics of transition zone reorganization during signaling events

• Cross-pathway analysis: Investigating how TMEM231 and the transition zone integrate multiple signaling pathways beyond the well-established Hedgehog pathway

Research has established that TMEM231 is essential for proper Hedgehog signaling, as demonstrated by the abrogated Hedgehog signaling in TMEM231 mutant embryos . Expanding these investigations to other pathways that function through primary cilia could reveal new roles for TMEM231 in cellular signaling networks.

What techniques can integrate TMEM231 antibody detection with analysis of ciliary membrane protein trafficking?

Researchers can integrate TMEM231 antibody detection with ciliary membrane protein trafficking analysis through:

• Pulse-chase experiments: Combine TMEM231 immunostaining with pulse labeling of ciliary membrane proteins to track entry and exit rates in wild-type versus TMEM231-mutant cells

• Photoactivatable proteins: Use photoactivatable fluorescent protein-tagged ciliary membrane proteins alongside TMEM231 immunostaining to track directional movement

• FRAP (Fluorescence Recovery After Photobleaching): Measure the recovery kinetics of fluorescently-tagged ciliary membrane proteins in cells with normal versus altered TMEM231 function

• Live-cell single-molecule tracking: Combine with fixed-cell TMEM231 immunostaining to correlate single-molecule behavior with transition zone structure

• Correlative light-electron microscopy: Use TMEM231 antibodies for immunogold labeling to examine transition zone ultrastructure in relation to membrane protein localization

These approaches can help distinguish between two competing models of TMEM231 function: whether the MKS complex acts primarily as an entry barrier (preventing inappropriate protein entry) or an exit barrier (retaining ciliary proteins while allowing exit of non-ciliary proteins) . Current research suggests the complex might influence both entry and exit rates of membrane proteins at the cilium.

How can researchers use TMEM231 antibodies to explore potential therapeutic approaches for ciliopathies?

TMEM231 antibodies can be instrumental in developing and evaluating therapeutic approaches for ciliopathies through:

• Therapeutic screening: Use TMEM231 antibodies to assess whether candidate compounds can restore proper transition zone architecture in cells with disease-causing mutations

• Biomarker development: Establish TMEM231 localization patterns or associated protein complexes as biomarkers for disease progression or treatment response

• Gene therapy validation: Verify successful gene therapy approaches by confirming proper TMEM231 expression and localization

• Drug mechanism studies: Elucidate how beneficial compounds affect TMEM231 stability, localization, or interaction with other transition zone components

• Patient stratification: Use TMEM231 antibodies to characterize patient samples for potential responsiveness to specific therapeutic approaches

The finding that disease-associated TMEM231 mutations are hypomorphic rather than complete loss-of-function suggests that approaches aimed at enhancing residual protein function or stability might be therapeutically beneficial. TMEM231 antibodies would be essential tools for validating such approaches, detecting even small improvements in protein localization or function that might translate to clinical benefit.